Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

By HospiMedica International staff writers
Posted on 16 Aug 2026

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. More...

Continuous high-dose regimens may initially shrink disease but can also favor resistant tumor clones, limiting long-term control. Clinicians therefore need early, noninvasive indicators to identify treatment strategies most likely to sustain response. Researchers have now developed mathematical biomarkers derived from routine blood tests to help guide adaptive therapy decisions in prostate cancer.

Researchers at the H. Lee Moffitt Cancer Center & Research Institute, working with the Wolfson Center for Mathematical Biology at Oxford University, developed three mathematical biomarkers calculated from prostate-specific antigen (PSA) measurements collected during the first treatment cycle. Adaptive therapy pauses treatment when disease is controlled and resumes it when tumor growth returns, with the goal of limiting the expansion of drug-resistant populations. The new biomarkers are designed to predict treatment response early enough to help determine whether a patient may benefit from an adaptive schedule or should remain on continuous therapy.

The three measures are the Adaptive Therapy (AT) Score, Expected Time to Progression (eTTP), and Expected Mean Daily Dose (eMDD). The AT Score estimates a patient’s potential benefit from adaptive therapy compared with continuous treatment. The eTTP projects how long disease control is likely to persist before regrowth, while the eMDD estimates average drug exposure over time under an adaptive regimen, providing an early indication of treatment burden. The framework relies only on first-cycle PSA data to model tumor behavior over time and can be calculated automatically by decision-support software without requiring additional biopsies.

Investigators evaluated the approach using data from 53 patients enrolled in two independent clinical studies. One cohort included 40 patients whose disease remained highly responsive to hormone therapy, while the second included 13 patients whose cancer had progressed despite effective testosterone suppression. Across both groups, the AT Score was strongly associated with time to progression. In the more advanced cohort, higher AT Scores and longer eTTP values were also associated with longer survival. Conventional PSA-derived measures showed substantially less ability to predict outcomes. The findings were published in JAMA Oncology on August 6, 2026.

The authors note that larger, prospective validations are needed before clinical adoption, but the measures could serve as a decision-support tool to better match patients to adaptive versus continuous strategies. The team is also adapting similar models for cancers with noninvasive tumor markers comparable to PSA, such as CA125 in ovarian cancer. If confirmed, this approach may help clinicians balance disease control with drug exposure while anticipating resistance earlier in the care pathway.

Related Links  
Moffitt Cancer Center


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hand-held Hemoglobin Analyzer
DiaSpect Tm
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image Credit: Shutterstock

Explainable AI Examines Sepsis Mortality Risk and Emergency Care Delays

Preventing sepsis-related deaths in emergency departments (EDs) remains challenging because patient deterioration can result from multiple rapidly evolving and interconnected factors. These include triage... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image: A new automated approach could help predict which patients with dystonia will benefit from deep brain stimulation before surgery (Image Credit: Adobe Stock)

AI Uses Routine MRI to Predict Deep Brain Stimulation Response in Dystonia

Dystonia is a debilitating neurological movement disorder characterized by involuntary muscle contractions that cause abnormal movements and postures. Deep brain stimulation (DBS) is one of the few treatments... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.